Search results
Results from the WOW.Com Content Network
The study included 294 participants who presented with symptoms of thrombocytopenia and thrombosis after receipt of the first dose of the Oxford–AstraZeneca COVID‑19 vaccine, showing an independent association between baseline platelet count and the presence of intracranial hemorrhage. The study established that 85% of the participants ...
Intraparenchymal hemorrhage is one form of intracerebral bleeding in which there is bleeding within brain parenchyma. The other form is intraventricular hemorrhage). [1] Intraparenchymal hemorrhage accounts for approximately 8-13% of all strokes and results from a wide spectrum of disorders.
Multisystem inflammatory syndrome in children (MIS-C), or paediatric inflammatory multisystem syndrome (PIMS / PIMS-TS), or systemic inflammatory syndrome in COVID-19 (SISCoV), is a rare systemic illness involving persistent fever and extreme inflammation following exposure to SARS-CoV-2, the virus responsible for COVID-19. [7]
Dr. Vivek Murthy, the U.S. Surgeon General, tweeted this week that his 4-year-old daughter has COVID. Here's why parents hoping for a vaccine can relate.
Children are less likely to become hospitalized than adults. [3] [13] [14] [15] Several explanations contributing to the milder COVID-19 symptoms experienced, in the acute phase, by children have been suggested, including: [16] [17] a lower expression of ACE-2 (the receptor used by SARS-CoV-2 for cell entry) in the respiratory tract in younger ...
The Medicines and Healthcare products Regulatory Agency last month authorised use of the Pfizer/BioNTech vaccine in children aged 12-15.
Longer-term effects of COVID-19 have become a prevalent aspect of the disease itself. These symptoms can be referred to by many names including post-COVID-19 syndrome, long COVID, and long haulers syndrome. An overall definition of post-COVID conditions (PCC) can be described as a range of symptoms that can last for weeks or months. [83]
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA).